Disruption of methionine metabolism drives erythroid cell fate reprogramming by remodeling the H3K4me3 landscape
Journal of Clinical Investigation · 2026
DOI: 10.1172/jci203565 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Lei Sun und 13 weiteren Autor:innen. Beteiligte Einrichtung: Aging Decoding and Regeneration Institute, School of Life Sciences, Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Histones, Methionine, Erythroid Cells, Erythroblasts. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The methionine cycle plays critical roles in cell fate determination by shaping epigenetic landscape, yet its function in human erythropoiesis remains undefined. Here, we show that disruption of methionine metabolism by compromising the key enzyme adenosylhomocysteinase (AHCY) reshapes H3K4me3 landscape, causing erythroid cell fate reprogramming. AHCY deficiency severely impaired erythroid differentiation and expansion, leading to the generation of nonerythroid lineage hematopoietic cells, including stem/progenitor cells and immune cells, as evidenced by single-cell RNA-seq, and pseudo temporal analysis delineated a precise dedifferentiation trajectory, revealing erythroblasts transitioning back to MEPs and HSCs. Moreover, the human hematopoietic system could be reconstituted in the immunodeficient NCG-X mice by transplanting AHCY-deficient erythroblasts. Mechanistically, AHCY deficiency reduced global H3K4me3 levels and altered its genomic distribution, resulting in the upregulated expression of nonerythroid transcription factors and downregulated expression of erythrocyte lineage-specific transcription factors. Integrated single-cell analyses identified transitional states with diminished AHCY in the erythroblasts of a patient with acute myeloid leukemia (AML). Further flow cytometry confirmed the reduced H3K4me3 level in patient-derived erythroid cells. Erythroblasts isolated from patients with AML with reduced H3K4me3 exhibited a dedifferentiation potential into progenitor-like states. Our findings reveal a metabolic-epigenetic axis governing cell fate reprogramming in human erythropoiesis and provide insights into leukemia-associated anemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Aging Decoding and Regeneration Institute, School of Life Sciences, Zhengzhou University, Zhengzhou, China.
- Department of Hematology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, China.
- Institute of Hematology, People's Hospital of Zhengzhou University, ZhengZhou, China.
- Department of Hematology, the Second Xiangya Hospital, Central South University, Changsha, China.
- Molecular Biology Research Center & Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Sun, L., Zhang, H., Li, M., Lin, Q., Wu, X., Cheng, Y., Wang, S., Hou, Y., Wang, Y., Sheng, Y., Liu, J., An, X., Wang, T., & Chen, L. (2026). Disruption of methionine metabolism drives erythroid cell fate reprogramming by remodeling the H3K4me3 landscape. Journal of Clinical Investigation. https://doi.org/10.1172/jci203565
Vancouver
Sun L, Zhang H, Li M, Lin Q, Wu X, Cheng Y, et al. Disruption of methionine metabolism drives erythroid cell fate reprogramming by remodeling the H3K4me3 landscape. Journal of Clinical Investigation. 2026. doi:10.1172/jci203565
BibTeX
@article{Sun2026,
author = {Sun, Lei and Zhang, Hengchao and Li, Mengjia and Lin, Quande and Wu, Xiuyun and Cheng, Ying and Wang, Shihui and Hou, Yan and Wang, Yaomei and Sheng, Yue and Liu, Jing and An, Xiuli and Wang, Ting and Chen, Lixiang},
title = {Disruption of methionine metabolism drives erythroid cell fate reprogramming by remodeling the H3K4me3 landscape},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci203565}
}
EUVIMED